Form 4: Director Ezra Friedberg Sells Pelthos Shares for Taxes

Director Ezra M. Friedberg sold 283 shares of Pelthos Therapeutics Inc. to satisfy tax obligations related to RSU vesting.

Summary

• Director Ezra M. Friedberg sold a total of 283 shares of Pelthos Therapeutics Inc. (PTHS) common stock on June 15, 2026.
• The sales were executed in two batches: 224 shares at a weighted average price of $27.1245 and 59 shares at a weighted average price of $27.9403.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on December 16, 2025.
• Following these transactions, the reporting person directly owns 81,600 shares, with additional indirect holdings through Balmoral Financial Group LLC and Key Recovery Group LLC.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale is clearly identified as a routine tax-related transaction under a pre-existing 10b5-1 plan.

Positives

• The sale was conducted under a pre-established Rule 10b5-1 trading plan, indicating the transaction was automated and not based on non-public information.

Negatives

• The filing reflects a reduction in direct equity ownership by a company director.

Risks

• The reporting person maintains significant indirect beneficial ownership in the company, which could be subject to market volatility.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Management Comments

• The reporting person confirms the sale was made to satisfy estimated tax obligations in connection with the vesting of restricted stock units.

Industry Context

StockSavvy.ai notes that insider sales executed via Rule 10b5-1 plans are standard corporate practice for managing tax liabilities associated with equity compensation and generally do not signal a change in management sentiment regarding company performance.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is a standard governance practice for executives and directors to avoid potential conflicts of interest regarding insider trading regulations.

Related Party Transactions

• The reporting person is the manager of Balmoral Financial Group LLC and Key Recovery Group LLC, which hold shares of the issuer.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was small and pre-planned for tax purposes.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Pelthos Therapeutics, PTHS, Insider Trading, Form 4, Equity Compensation, Rule 10b5-1